Dr. Shaheed M. Ali, MD
Internal Medicine (Internal Medicine Physician)
At a glance
- Medical school
- New York University School of Medicine (1982)
- Years since graduation
- 44
- In the NPI registry since
- 2019
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 1982Medical school: New York University School of Medicine
- 2019Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
FL license ME44380 -
Rheumatology Physician
FL license ME44380
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 5 companies reported 11 payments worth $249 in total to this clinician.
| UCB, Inc. | $122 |
|---|---|
| Genentech USA, Inc. | $42.97 |
| GlaxoSmithKline, LLC. | $39.26 |
| Alexion Pharmaceuticals, Inc. | $27.82 |
| AstraZeneca Pharmaceuticals LP | $16.89 |
| Food and Beverage | $249 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 5 companies. The companies reported $106,017 in research payments for these studies, mostly to the institutions running them.
- An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis
Eli Lilly and Company · Completed · NCT05848258 - Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent
Janssen Research & Development, LLC - LUPKYNIS Registry Study
Aurinia Pharma U.S., Inc. - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
AbbVie Inc. · Active, not recruiting · NCT02629159 - M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
AbbVie Inc. - INSPIRE LTE study
Sun Pharmaceutical Industries Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.